Which Medications Treat Diabetes—and Is Sezime Hibemib Tablet for Blood Sugar Control or Cholesterol Only?

Several classes of medications are approved for the treatment of type 2 diabetes, each with distinct mechanisms of action and clinical indications. First-line therapy typically includes metformin, which improves insulin sensitivity and reduces hepatic glucose production. Other widely used agents include sulfonylureas (e.g., glipizide, glyburide), DPP-4 inhibitors (e.g., sitagliptin, linagliptin), SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin), GLP-1 receptor agonists (e.g., semaglutide, dulaglutide), and insulin formulations for more advanced disease.

Sezome (bempedoic acid) is not an antihyperglycemic agent—it is a first-in-class ATP-citrate lyase (ACL) inhibitor approved exclusively for the management of hypercholesterolemia and mixed dyslipidemia. It lowers low-density lipoprotein cholesterol (LDL-C) by inhibiting cholesterol synthesis in the liver, and it is indicated as an adjunct to maximally tolerated statin therapy or as monotherapy in statin-intolerant patients. Importantly, bempedoic acid has no clinically meaningful effect on blood glucose levels and is not approved—and should not be used—for glycemic control.

Clinical trials, including the CLEAR Outcomes study, demonstrated that bempedoic acid significantly reduced major adverse cardiovascular events in high-risk patients with elevated LDL-C, reinforcing its role in cardiovascular risk reduction—not diabetes management. While some lipid-lowering agents (e.g., certain fibrates or PCSK9 inhibitors) may have modest secondary effects on glucose metabolism, bempedoic acid lacks such activity and does not influence HbA1c, fasting plasma glucose, or insulin resistance.

Healthcare providers must distinguish between lipid-modifying and glucose-lowering therapies when designing individualized treatment plans. Concomitant use of bempedoic acid and antidiabetic agents is appropriate in patients with both dyslipidemia and diabetes—but only because the two conditions frequently coexist, not because bempedoic acid exerts any antihyperglycemic effect.